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Safety and Efficacy of Hydroxychloroquine in COVID-19: A
Systematic Review and Meta-Analysis
Waqas Ullaha, i, Hafez M. Abdullahb, Sohaib Roomia, Yasar Sattarc, Talal Almasd,
Smitha Narayana Gowdab, Rehan Saeeda, Maryam Mukhtare, Ammar Ahmadf,
Tony Oliverb, M. Chadi Alraiesg, Donald C. Haasa, David L. Fischmanh

Abstract
Background: During the initial phases of the coronavirus disease
2019 (COVID-19) epidemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ); however, recently,
the Centers for Disease Control and Prevention (CDC) has recommended against routine use of HCQ outside of study protocols citing
possible adverse outcomes.
Methods: Multiple databases were searched to identify articles on
COVID-19. An unadjusted odds ratio (OR) was used to calculate the
safety and efficacy of HCQ on a random effect model.
Results: Twelve studies comprising 3,912 patients (HCQ 2,512 and
control 1400) were included. The odds of all-cause mortality (OR:
2.23, 95% confidence interval (CI): 1.58 - 3.13, P value < 0.00001)
were significantly higher in patients on HCQ compared to patients
on control agent. The response to therapy assessed by negative repeat polymerase chain reaction (PCR) (OR: 1.83, 95% CI: 0.50 6.75, P = 0.36), radiological resolution (OR: 1.98, 95% CI: 0.47
- 8.36, P value = 0.36) and the need for invasive mechanical ventilation (IMV) (OR: 1.21, 95% CI: 0.34 - 4.33, P value = 0.76) were
identical between the two groups. Overall, four times higher odds of
net adverse events (NAEs) were observed in the HCQ group (OR:
4.59, 95% CI 1.73 - 12.20, P value = 0.02). The measures for individual safety endpoints were also numerically lower in the control
arm; however, none of these values reached the level of statistical
significance.
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Conclusions: HCQ might offer no benefits in terms of decreasing the
viral load and radiological improvement in patients with COVID-19.
HCQ appears to be associated with higher odds of all-cause mortality
and NAEs.
Keywords: COVID-19; SARS-CoV-2; HCQ; CQ

Introduction
On March 11, 2020, the World Health Organization (WHO)
officially declared coronavirus disease 2019 (COVID-19) a
global pandemic. Emerging as a handful of pneumonia case
clusters in Wuhan, China, in late December 2019, COVID-19
has now reached all corners of the world. The epicenter of the
outbreak has shifted over the past 4 months from China to Italy and now to New York. As of April 28, 2020, more than 3
million cases from over 180 countries and more than 200,000
deaths have been documented worldwide, with the USA accounting for nearly a quarter of all fatalities. The projected
number of deaths in the USA is between 100,000 and 240,000,
with an estimated total burden of over 2 million COVID-19
cases [1].
In response to this extraordinary public health challenge
and the urgent need for medications to treat this disease, the
Food and Drug Administration (FDA) established a Coronavirus Treatment Acceleration Program (CTAP) and issued
Emergency Use Authorization (EUA) for chloroquine (CQ)
and its derivative hydroxychloroquine (HCQ). CQ and HCQ
(an analog of CQ) are primarily approved for the treatment
of malaria and chronic inflammatory disorders (rheumatoid
arthritis), respectively [2]. Scientific literature pertaining to
the immunopathology of the severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome virus
(MERS) has previously shown some effect of these medications against those viruses [3]. This lends some credence to
the use of these medications against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both drugs are
thought to prevent the ingress of virions into the host cell, halt
post-entry cascades and replication of the virus. The former
is achieved by inhibition of the downstream glycosylation of
angiotensin-converting enzyme 2 (ACE2) receptors, while en-
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dosomal acidification helps in reducing the overall virus burden [2-4].
Although HCQ was widely adopted for the treatment of
COVID-19, this appears to have been based on little concrete
evidence, but rather on anecdotal data emerging from China
and France. While a few small-scale studies have demonstrated some favorable outcomes, the safety and efficacy of these
regimens remain to be proven. This, along with considerable
concern for HCQ-related adverse outcomes, has prompted us
to conduct this meta-analysis as we await the results of randomized control trials (RCTs).

Materials and Methods
Search strategy and data extraction
The MEDLINE (PubMed, Ovid), EMBASE, Clinicaltrials.
org and Cochrane databases were queried with various combinations of medical subject headings (MeSH) to identify
relevant articles. There were no language or time restrictions
placed. Backward snowballing was performed to retrieve unidentified studies that were missed on the initial search. The
MeSH used included two subsets: one for the COVID-19 and
another for HCQ. The two subsets of MeSH were combined
in a 1:1 combination using Boolean operators. Results from
all possible combinations were downloaded into an EndNote
library. All RCTs and observational cohort studies (OCSs)
until April 30, 2020, were evaluated. Studies comparing
the safety and efficacy of the HCQ in COVID-19 were included. The efficacy endpoints were radiological resolution
or decreased virological load on repeat polymerase chain reaction (PCR). Safety outcomes included net adverse events
(NAEs), a composite of gastrointestinal, respiratory, neurological and dermatological outcomes. Secondary outcomes
included components of NAE. Review articles, conference
papers, and studies with no control arm or insufficient data
were excluded.
Data analysis
The statistical analysis was performed using the DerSimonian
and Laird test on a random-effects model to calculate an unadjusted odds ratio (OR). The probability value of P < 0.05 was
considered statistically significant. The “test for overall effect”
was reported as a z-value corroborating the inference from the
95% confidence interval (CI). If the eligibility of a study was
dubious or unduly influencing results due to its large sample
size, a sensitivity analysis was performed. Subgroup analysis
based on the type of control group (placebo vs. antiviral) was
also performed. Higgins I-squared (I2) statistical model was
used to assess variations in outcomes of the included studies. I2
less than 40% corresponded to low heterogeneity. Depending
upon the strength of evidence for heterogeneity (P value from
the Chi-square χ2 analysis), I2 of 41-74% indicated moderate (P
≥ 0.05) or moderate to severe (P ≤ 0.05), and I2 of 75% or higher suggested substantial heterogeneity. Publication bias was il484
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lustrated graphically using a funnel plot. The methodological
quality assessment of the included RCTs was performed using
the Cochrane collaboration tool for the systematic review and
meta-analysis, where each study was screened for five different types of bias (selection, performance, detection, attrition,
and reporting bias). All statistical analysis was performed using the Digitize and the Cochrane Review Manager (RevMan)
version 5.3.
Quality of the included studies
The overall quality of the included RCTs was high (Fig. 1).
Due to adequate randomization and allocation concealment,
the risk of selection bias in RCTs was low. However, three
retrospective cohort studies introduced a 30% overall risk of
selection bias. The risks of performance and detection bias
were high because of inadequate blinding of participants and
outcomes, respectively. Reporting bias across all studies was
reduced due to an adequate description of the study results.
The fact that most RCTs used an intention to treat model or
had a minimal loss to follow-up of its participants, the risk of
attrition bias was minimal.
An approval was obtained from the Institutional Review
Board (IRB).

Results
Search results and study characteristics
The initial search revealed 351 articles. After removal of irrelevant and duplicate items, 160 articles were deemed relevant for full-text review. Of these, 148 articles were excluded based on our selection criteria. Fourteen articles (seven
RCTs, seven OCSs) qualified for quantitative analysis [5-18].
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram is shown in Figure
2.
A total of 3,912 patients, 2,512 in HCQ and 1,400 in the
control arm were included. The mean age was 51 years, comprising 65% male patients. Eight studies compared HCQ therapy to standard of care therapy (SCT) on outcomes including
mortality, viral clearance and radiological resolution. SCT is
defined as a supportive therapy with no specific treatment for
COVID-19. The study of Borba et al compared high dose HCQ
(600 mg twice daily) with low dose HCQ (450 mg twice daily)
[9]. Huang et al compared HCQ against lopinavir/ritonavir
therapy [8]. Carlucci et al compared HCQ + azithromycin +
zinc with HCQ + azithromycin in the control group [14]. The
baseline characteristics were comparable between the HCQ
and the control group with a proportion of hypertension (26%
vs. 21.5%), diabetes mellitus (23% vs. 21%), smoking (23.6%
vs. 20.5%) and chronic kidney disease (11.7% vs. 13%), respectively. The follow-up period varied from 6 days to 28 days
with a median follow-up duration being 7 days. The detailed
account of the inclusion criteria of studies and the baseline
characteristics of included patients are given in Supplementary
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Figure 1. Methodological quality assessment of the included studies.

Material 1 (www.jocmr.org).
Pooled analysis of efficacy endpoints
A comprehensive pooled analysis of 12 studies did not show

any benefit with the use of HCQ in any of the efficacy endpoints. Virological clearance assessed by negative repeat PCR
(OR: 1.83, 95% CI: 0.50 - 6.75, P = 0.36) and radiological
resolution of concerning findings for COVID-19 (OR: 1.98,
95% CI: 0.47 - 8.36, P = 0.36) were similar between the two
groups. The in-hospital requirement for an invasive mechani-
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Figure 2. PRISMA flow diagram of the included studies in systematic review and meta-analysis. PRISMA: Preferred Reporting
Items for Systematic Reviews and Meta-Analyses.

cal ventilation (IMV) (OR: 1.21, 95% CI: 0.34 - 4.33, P = 0.76)
was also identical between patients on HCQ compared to those
not on HCQ. There was no significant difference between the
disease progression between the two groups (OR: 2.06, 95%
CI: 0.26 - 16.40, P = 0.50), while, HCQ was found to be associated with significantly higher odds of all-cause mortality
(OR: 2.23, 95% CI: 1.58 - 3.13, P value < 0.00001) compared
to patients in the control group. The heterogeneity in the outcomes of the included studies was moderate to high (I2 = 54%
- 94%) (Figs. 3, 4a).
Pooled analysis of safety endpoints
The incidence of NAE, a composite of all systemic complications, was used to gauge the safety of HCQ. The NAE with
HCQ was significantly higher in the HCQ group as compared
to control groups (OR: 4.59, 95% CI: 1.73 - 12.20, P value =
0.02) (Fig. 4b). Interestingly, the odds of all individual adverse events were consistently higher but statistically nonsignificant in patients receiving HCQ for COVID-19; respiratory complications (OR: 1.19, 95% CI: 0.52 - 2.73, P value
= 0.68), gastrointestinal complications (OR: 1.45, 95% CI:
0.66 - 3.11, P value = 0.35), neurological adverse symptoms
(OR: 1.26, 95% CI: 0.20 - 7.98, P value = 0.81), dermatological side effects (OR: 3.55, 95% CI: 0.35 - 35.93, P = 0.28),
cardiac arrest (OR: 0.88, 95% CI: 0.33 - 2.39, P value = 0.81)
(Fig. 5). In the study of Borba et al [9], a high dose of HCQ
was associated with a higher rate of QT prolongation, and
486

ventricular arrhythmias.
Subgroup sensitivity analysis
Subgroup sensitivity analysis based on the type of medications
used in combination with HCQ in the experimental group mirrored the overall findings of all efficacy endpoints except that
mechanical ventilation was lower in the study by Carlucci et al
[14], and control agent was favored in the study by Gautret et
al [5] in terms of virological seroconversion. The safety profile
was in concordance with the pooled results for all subgroups
(Supplementary Materials 2 - 4, www.jocmr.org).
Publication bias
On visual assessment of the funnel plots, publication bias was
minimal for overall outcomes (Fig. 6). The vertical axis of the
plot used the standard error to estimate the sample size of the
study; it is evident that the majority of the included studies fall
at the bottom, indicating a small sample size. The horizontal
spread reflected that most studies were underpowered due to a
wide CI of the effect size.

Discussion
Our meta-analysis of 14 studies comprising 3,816 patients
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Figure 3. Forest plot for (a) virological cure, (b) radiological improvement, (c) ventilator required, and (d) progression to severe
illness showing an individual and pooled OR for studies comparing HCQ-treated patients with control. OR: odds ratio; HCQ:
hydroxychloroquine.

showed no significant difference in the efficacy of HCQ compared to the control arm, while the overall NAEs were five
times higher in in the former group [5-16]. The individual safety measures including the incidence of gastrointestinal, respiratory, cardiac, dermatological and neurological complications were numerically higher but statistically non-significant
between the two groups. Efficacy was gauged by a difference
in the mortality rate, decrease in the viral load and radiological resolution of COVID-19-related findings. While there was
no significant difference in most of the efficacy endpoints, patients on HCQ had a two-fold higher rate of in-hospital allcause mortality compared to patients on SCT.

Of the included studies, the major efficacy endpoint referred to the attainment of a negative PCR result, indicating total viral clearance usually at 5 - 10 days of treatment. A pooled
analysis of five studies comprising 268 patients revealed that
a virologic cure was achieved in 84% of patients treated with
HCQ compared to 77% in the control group. Gautret et al presented the results of a 14-day trial with 36 patients [5]. This
was an outlier as the only study that had a statistically significant improvement in virologic cure rate. It is unclear if these
findings could be attributed to the substantial amount of attrition and performance bias seen in this study [5]. Six patients
on HCQ were prematurely excluded before completion of the
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Figure 4. Forest plot for (a) all-cause mortality, and (b) NAE, showing an individual and pooled OR for studies comparing HCQtreated patients with control. NAE: net adverse event; OR: odds ratio; HCQ: hydroxychloroquine.

study, and there were inconsistencies in the methods and centers of PCR testing between the two groups. Nevertheless, this
study triggered massive interest and prompted other researchers to further evaluate the efficacy of HCQ. These subsequent
studies have, however, shown an identical rate of virological
clearance among both the HCQ-treated and SCT groups, mirroring the findings of our pooled analysis. It should be noted
that the wide CI in our results indicates that it is difficult to draw
definitive conclusions from the limited data currently available.
Three studies included in our analysis reported resolution of suggestive radiological findings on computerized tomography (CT) as an efficacy outcome [6-8]. A pooled analysis of these studies that comprised 56 (HCT) and 58 patients
(SCT group) showed a trend favoring resolution in the HCQ
group (71% vs. 57%), though statistical significance was
not achieved. Huang et al was the only study that provided a
breakdown of radiologic features. They reported a higher percentage of patients in the control group with the involvement
of more than two lobes and also bilateral distribution of patchy
shadows (92% vs. 60% and 91% vs. 60%, respectively) [8].
The most debilitating complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
acute respiratory failure necessitating the use of IMV and other
concurrent resource-intensive needs in critical care units [10].
The need for artificial ventilation was reported by four studies,
comprising 1,357 patients in the HCQ and 919 patients in the
control group, showing 11% vs. 14% utilization, respectively,
with a pooled OR of 0.86 [9, 10, 14, 15]. While this favors the
HCQ group, it was statistically not significant with P value
of 0.24. Among these four studies, we found that the study
of Magagnoli et al was not only subject to the bias of nonrandomized data but also to ascertainment issues, i.e., sicker
488

patients were more likely to receive HCQ on compassionate
grounds and hence were more prone to have adverse outcomes
[10].
Our mortality analysis of 3,004 (HCQ group: 1,907; control: 1,097) showed a significantly higher rate of all-cause
mortality in patients in HCQ group compared to those on SCT.
It should be noted, however, that this difference is principally
driven by three out of 12 studies with higher population [1416]. Magagnoli et al reported a mortality rate three times higher in the HCQ group than the SCT group [10]. This finding is
likely reflective of the inclusion of a sicker population in the
treatment group, as evidenced by the higher rate of lymphopenia and azithromycin use. The study by Borba et al differed in
terms of its inclusion criteria, comparing a high dose of HCQ
against a low dose of HCQ [9]. Similarly, Carlucci et al studied
the efficacy of HCQ, azithromycin, and zinc against HCQ and
azithromycin, demonstrating increased frequency of discharges (OR: 1.53, 95% CI: 1.12 - 2.09) and low mortality (OR:
0.449, 95% CI: 0.271 - 0.744) in the zinc regimen arm [14].
On the contrary, Rosenberg et al compared SCT with HCQ and
azithromycin, or HCQ alone, favoring the control arm due to
a significantly lower need for IMV and mortality [15]. These
findings were validated by Geleris et al [16]. Overall, the inconsistencies in the results of the included studies indicate that
currently there is not enough data available to confirm or refute
the efficacy of HCQ in this patient population, and we would
have to wait for further studies to be reported before a more
accurate assessment can be made [16].
While the therapeutic benefits of HCQ have now been
widely touted, the adverse effects have not been adequately
highlighted. In the current context, HCQ is generally thought
to be safe due to a typically short course of therapy employed
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Figure 5. Forest plot for (a) respiratory complications, (b) gastrointestinal complications, (c) dermatological side effects, (d)
neurological complications and (e) cardiac arrest showing an individual and pooled OR for all studies comparing HCQ treated
patients with control. OR: odds ratio; HCQ: hydroxychloroquine.

for COVID-19. Our overall analysis showed a significantly
higher incidence of NAEs in patients on HCQ. The individual
components of the composite were also numerically higher in
the HCQ arm. On analysis of 1,220 patients, only 29% of the
SCT group developed adverse reactions compared to 77% of
patients receiving HCQ. The neurological (1.8% vs. 1.6%),
respiratory (7.5% vs. 6.5%), cardiac (35% vs. 35%), and gastrointestinal (18% vs. 8%) complications were higher in the
HCQ vs. SCT, respectively. A study by Rosenberg et al reported a higher incidence of cardiac arrest with a combination of

HCQ and azithromycin (OR: 2.13, 95% CI: 1.12 - 4.05) [15].
In light of these trends and with previous studies demonstrating major side effects of HCQ (cardiomyopathy, QT prolongation, and retinopathy), a considered risk to benefit determination should be made prior to HCQ use.
In summary, the available data regarding the effect of HCQ
on safety and efficacy are limited and fraught with inconsistencies. A better analysis may be possible once more data become
available from the numerous trials that are currently underway.
However, it is important to keep in mind that the virologic cure
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Figure 6. Funnel plot showing possible publication bias across all studies and subgroups.

does not necessarily correlate with the resolution of symptoms
and patient outcomes. At present, our analysis shows that HCQ
use is not associated with any benefit and could potentially be
harmful.
Limitations
Our study is constrained by the limitations of the included
studies. All studies were vastly underpowered due to the small
sample size. There was significant heterogeneity in the inclusion criteria limiting our ability to perform subgroup analysis.
Some therapeutic decisions were impacted by the prescriber’s
discretion, prioritizing treatment of the sicker population, potentially skewing results. Variability in the doses of HCQ, addition of antiviral agents to control arms, differing PCR testing methods and paucity of major RCTs call for caution while
interpreting the results of this meta-analysis.

Comorbidities Among Included Studies (Data Presented in Experimental/Control Group Pattern).
Suppl 2. Subgroups forest plot for ventilator required, virologic cure, and radiological improvement showing an individual
and pooled OR for studies comparing HCQ-treated patients
with control.
Suppl 3. Subgroup forest plot for all-cause mortality, sensitivity analysis of mortality, and progression to severe illness
showing an individual and pooled OR for studies comparing
HCQ-treated patients with control.
Suppl 4. Forest plot for net adverse events, respiratory complications, and cardiac arrest (left side); dermatologic complications, GI complications, and neurological complications (right
side), showing an individual and pooled OR for all studies
comparing HCQ-treated patients with control.
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